{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:01:19Z","timestamp":1780995679468,"version":"3.54.1"},"reference-count":12,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08DK129829"],"award-info":[{"award-number":["K08DK129829"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI181729-6885"],"award-info":[{"award-number":["U19AI181729-6885"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aramont Charitable Foundation"},{"DOI":"10.13039\/100000862","name":"Doris Duke Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitor (ICI) cancer therapies targeting programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 enhance antitumor immunity in many cancers. Despite its efficacy, ICI therapy can trigger severe autoimmune attacks across various organ systems, termed immune-related adverse events (irAEs). Antitumor immunity and autoimmunity are tightly linked as demonstrated by the enhanced efficacy of ICI therapy in patients who develop irAEs. Whether patients with preexisting autoimmunity or genetic risk factors for autoimmunity should be offered ICI therapies remains uncertain. We present the case of a patient with autoimmune polyglandular syndrome type 1, caused by a pathogenic autoimmune regulator (AIRE) missense mutation, who was treated with ICI therapy for squamous cell carcinoma of the hard palate. She subsequently developed 3 concurrent irAEs: ICI-hepatitis, ICI-thyroiditis, and ICI-diabetes mellitus. For these irAEs, the patient was treated with immunosuppressants, thyroid hormone replacement, and basal bolus insulin therapy. This case highlights the need for careful evaluation of patients for underlying autoimmune diseases prior to ICI therapy initiation. It also highlights a 2-hit model wherein any impaired central immune tolerance combined with ICI therapy may predispose patients to multiple severe irAEs.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag112","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:45:45Z","timestamp":1775043945000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1"],"prefix":"10.1210","volume":"4","author":[{"given":"Alexandra","family":"Lim","sequence":"first","affiliation":[{"name":"Division of Endocrinology, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-6327","authenticated-orcid":false,"given":"Esther M","family":"Peluso","sequence":"additional","affiliation":[{"name":"UCLA\/California Institute of Technology Medical Scientist Training Program, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 ,","place":["USA"]},{"name":"Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A","family":"Downs","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-0089","authenticated-orcid":false,"given":"Brian H","family":"Horwich","sequence":"additional","affiliation":[{"name":"Division of Transplant Hepatology, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A","family":"Velez-Velez","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-6566","authenticated-orcid":false,"given":"Melissa G","family":"Lechner","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 ,","place":["USA"]},{"name":"Division of Endocrinology, Greater Los Angeles Veterans Affairs Healthcare , Los Angeles, CA 90073 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"7","key":"2026060904161425100_luag112-B1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"2026060904161425100_luag112-B2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026060904161425100_luag112-B3","volume-title":"StatPearls","author":"Bello","year":"2025"},{"issue":"6","key":"2026060904161425100_luag112-B4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.oraloncology.2006.07.005","article-title":"Oral and oesophageal squamous cell carcinoma\u2013a complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I)","volume":"43","author":"Rautemaa","year":"2007","journal-title":"Oral Oncol"},{"issue":"5","key":"2026060904161425100_luag112-B5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/thy.2021.0685","article-title":"Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's thyroiditis","volume":"32","author":"Mosaferi","year":"2022","journal-title":"Thyroid"},{"issue":"8","key":"2026060904161425100_luag112-B6","doi-asserted-by":"crossref","first-page":"103135","DOI":"10.1016\/j.autrev.2022.103135","article-title":"Autoimmune polyendocrine syndrome type 1: clinical manifestations, pathogenetic features, and management approach","volume":"21","author":"Bj\u00f8rklund","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"7","key":"2026060904161425100_luag112-B7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"2026060904161425100_luag112-B8","doi-asserted-by":"crossref","first-page":"dgaa553","DOI":"10.1210\/clinem\/dgaa553","article-title":"ICPis-induced autoimmune polyendocrine syndrome type 2: a review of the literature and a protocol for optimal management","volume":"105","author":"Shi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060904161425100_luag112-B9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s40425-019-0713-y","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature","volume":"7","author":"Gunjur","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2026060904161425100_luag112-B10","doi-asserted-by":"crossref","first-page":"oyaf134","DOI":"10.1093\/oncolo\/oyaf134","article-title":"Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer","volume":"30","author":"LeVee","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"2026060904161425100_luag112-B11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1158\/2326-6066.CIR-18-0912","article-title":"Pulling RANK on cancer: blocking aire-mediated central tolerance to enhance immunotherapy","volume":"7","author":"Su","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2026060904161425100_luag112-B12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/7\/luag112\/68492724\/luag112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/7\/luag112\/68492724\/luag112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:16:19Z","timestamp":1780992979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag112\/8704253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5,20]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag112","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,20]]},"article-number":"luag112"}}